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Abstract : In this study, a highly sensitive method to simultaneously quantify the 
integrase strand transfer inhibitors （INSTIs） raltegravir, dolutegravir, elvitegravir, and 
bictegravir, which are recommended drugs in the HIV treatment guidelines, was 
established using liquid chromatography–tandem mass spectrometry （LC-MS/MS）.  
Raltegravir-d3 was used as the internal standard substance.  The plasma samples 
were deproteinized with methanol and analyzed by LC-MS/MS.  Chromatographic 
separation was performed using the gradient method with a mobile phase A 
（20 mmol/l ammonium formate - water） and mobile phase B （20 mmol/l ammo-
nium formate - methanol）.  In addition, an InertSustain C18 column （3 µm, 100 ×
2.1 mm）, a ow rate of 0.45 ml/min, and a measurement time of 10 minutes were 
used.  The calibration curve showed linearity （r2＞ 0.9904） within the range of 0.5-
1,250 ng/ml, and the limit of quantication was 0.5 ng/ml for all drugs.  The mean 
intra- and inter-day accuracy was 99.6％± 7.2％ and 101.0％± 5.0％, respectively, 
and the coefcient of variation （CV） was ≤ 18.5％ and ≤ 10.3％, respectively.  This 
method enables the highly sensitive simultaneous analysis of INSTIs and is useful 
for conrming the efcacy and safety of drugs in clinical practice.
Key words : integrase strand transfer inhibitors, LC-MS/MS, human plasma concen-
trations, simultaneous determination, therapeutic drug monitoring
Introduction
　The life expectancy of HIV-infected patients has been greatly improved by antiretroviral 
therapy （ART）, which is a combination of several anti-HIV drugs1）.  The United States 
Department of Health & Human Services guidelines recommend a regimen that includes a 
combination of integrase strand transfer inhibitors （INSTIs） and nucleoside reverse transcriptase 
inhibitors （NRTIs） as the initial therapy for treatment-naïve patients2）.  The INSTIs that have 
been approved by the Food and Drug Administration （FDA） and Japan are raltegravir （RAL）, 
dolutegravir （DTG）, elvitegravir （EVG）, and bictegravir （BIC）.  
　RAL is the world’s rst INSTI.  Importantly, RAL is not metabolized by cytochrome P450 
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（CYP） and is primarily metabolized through glucuronic acid conjugation mediated by uridine 
diphosphate （UDP） glucuronosyltransferase （UGT） 1A1.  Therefore, only a few drug-drug inter-
actions have been reported for RAL3）.  Drug interactions affect not only anti-HIV drugs, but 
they also affect concomitant drugs.  Because there are minimal drug-drug interactions with RAL, 
it is a useful agent when a patient is taking a concomitant drug.  The comparable efcacy of 
DTG and RAL was demonstrated in a randomized controlled trial （Phase Ⅲ） that included a 
group treated with 2 NRTIs and RAL4）.  DTG is primarily a substrate for UGTs, whereas only 
a small amount is metabolized by CYPs.  Signicantly, HIV has not yet developed resistance 
to DTG, which can be administered orally at a dose of 50 mg twice daily to patients who are 
resistant to other integrase inhibitors5）.  The two types of EVG that have been approved for use 
as a combination drug therapy are elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine 
（EVG/COBI/TDF/FTC）6） and elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine （EVG/
COBI/TAF/FTC）7）, with a recommended dose of one tablet a day.  COBI, a component of 
these combination therapies, is a potent CYP3A4 inhibitor and acts as a pharmacokinetic （PK） 
enhancer of EVG （booster）.  Therefore, if concomitant drugs are metabolized by CYP, their 
metabolism is inhibited by COBI.  For this reason, it is essential to consider drug-drug interac-
tions when prescribing these drugs.  RAL, DTG, and BIC can be taken with or without meals, 
but EVG must be taken with or directly after a meal.  BIC was recently approved in Japan in 
March 2019 as part of the BIC/TAF/FTC regimen.  The non-inferiority of the antiviral effect 
of the BIC group compared with the DTG group was demonstrated in a controlled trial （GS-
US-380-1490） that included HIV-infected treatment-naïve patients8）.  Similar to DTG, BIC has 
a high genetic barrier to the development of resistance and can be an option for patients with 
poor adherence.  Because BIC is a substrate for CYP3A and UGT1A1, it is contraindicated in 
combination with an enzyme inducer of drug metabolism, such as rifampicin and antiepileptics9）. 
At present, BIC is not widely used in Japanese patients, so it is necessary to determine its ef-
cacy and potential side effects.
　The therapeutic effects and tolerability of INSTIs are superior to other antiretrovirals, and 
INSTIs are administered to patients in clinical practice to both treatment-naïve and treatment-
experienced HIV patients.  Maintaining adherence is important to attain the therapeutic effect 
of anti-HIV drugs.  However, the plasma drug concentration can vary depending on individual 
patient differences and drug interactions.  Therefore, therapeutic drug monitoring （TDM） of anti-
HIV drugs is useful to manage their therapeutic effect and safety10, 11）.  
　Currently, INSTIs are measured alone or simultaneously with other anti-HIV drugs using liquid 
chromatography–tandem mass spectrometry （LC-MS/MS）.  Bennetto et al. measured DTG in 
small plasma samples （20 µl） and applied this method to pediatric clinical trials12）.  Prathipati 
et al. developed an LC-MS/MS method for the quantification of BIC in human plasma and 
reported its application in intracellular uptake studies13）.  In a PK and TDM study, Aouri et al. 
simultaneously measured EVG together with a rilpivirine （RPV） of non-nucleoside analogue 
reverse transcriptase inhibitor （NNRTI）14）.  Barceló et al. simultaneously measured EVG and 
COBI and reported population PK analyses and drug-drug interactions for EVG and COBI15）. 
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Fayet et al. reported the simultaneous measurements of four different classes of HIV drugs :  
darunavir （DRV）, etravirine （ETR）, maraviroc （MVC）, and RAL16）.  Yamada et al. reported 
the quantication of abacavir （ABC）, tenofovir （TFV）, DRV, and RAL in human plasma and 
saliva17）.
　The simultaneous measurement of anti-HIV drugs in human plasma, including multiple INSTIs, 
has been achieved by using LC-MS/MS.  Tsuchiya et al. measured RAL, EVG, and DTG in 
plasma and cerebrospinal uid （CSF）18）.  Penchala et al. measured plasma DTG and EVG19）. 
Simiele et al. simultaneously measured plasma levels of 18 anti-HIV drugs, including RAL, EVG, 
and DTG20）.  These reported methods have a limit of quantication of ≥ 5 ng/ml and a measure-
ment range of 5-4,000 ng/ml.  To date, there are no highly sensitive methods to measure the 
plasma concentration of the four INSTIs recommended by the current HIV treatment guidelines 
in the same measurement system.  Here, we report the development of a method that allows 
the simultaneous quantication of RAL, DTG, EVG, and BIC in human plasma using LC-MS/




　RAL, DTG, EVG, BIC, and RAL-d3 were purchased from Toronto Research Chemicals 
（North York, ON, Canada）.  Methanol （MeOH）, ultrapure water, acetonitrile, and ammonium 
formate were purchased from FUJIFILM Wako Pure Chemical Corporation （Osaka, Japan）. 
Fresh frozen plasma （FFP-LR120） was purchased from NISSEKI （Tokyo, Japan）.
Preparation of the calibration curve and quality control standards
　RAL, EVG, and BIC stock solutions were prepared in a 50％ MeOH solution （MeOH-water 
50 : 50, v/v） at 1.0 mg/ml.  The DTG stock solution was prepared in 50％ MeOH at 0.5 mg/
ml.  The internal standard （IS） RAL-d3 was prepared in 100％ MeOH at 1.0 mg/ml.  The RAL, 
EVG, DTG, and BIC working solutions were diluted with 50％ MeOH to 10,000 ng/ml, and the 
IS was diluted with 100％ MeOH to 1,000 ng/ml.  
　The standard solutions for the calibration curve were 0.5, 5, 20, 50, 250, 500, and 1,250 ng/ml, 
using human plasma as the matrix.  Solutions of 0.5 ng/ml （lower limit of quantication quality 
control ［QC］, LLQC）, 1.0 ng/ml （low QC, LQC）, 100 ng/ml （mid QC, MQC）, and 1,000 ng/
ml （high QC, HQC） of human plasma were prepared as QC samples.  The calibration standards 
and QC samples were stored at －30℃.  
Clinical samples
　Clinical samples were obtained from six patients with an HIV-1 infection who were receiving 
ART, including RAL, DTG, EVG, and BIC at the AIDS Clinical Center, National Center for 
Global Health and Medicine.  The plasma samples were collected in heparin blood collection 
tubes and subsequently centrifuged at 3,000 × g for 10 minutes ; the obtained plasma was stored 
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at －80℃.  This study was approved by the ethics committee of the National Center for Global 
Health and Medicine （NCGM-A-003058-02）, and each patient provided their informed consent.  
Sample preparation
　In this analysis method, a CLAM-2000 （Shimadzu, Kyoto, Japan） was used for the prepara-
tion of precipitated proteins, which were prepared at 9℃ with fully automated sampling.  First, 
150 µl of the plasma samples were dispensed into a vial and set in CLAM.  In CLAM, 20 µl 
of MeOH was added to the lter, and the lter was activated.  After activation of the lter, 
30 µl of the plasma sample was added, then 100 µl of MeOH and 10 µl of the IS were added. 
The plasma sample was stirred at 1,900 rpm （15 × g） for 60 s, ltered for 90 s, and 5 µl of the 
prepared sample was injected for LC-MS/MS analysis.  Clinical samples were diluted 10-fold with 
blank human plasma to obtain drug concentrations within the linear range of the assay.
LC-MS/MS analysis
　Chromatographic separation was performed using the Nexera System （Shimadzu, Kyoto, Japan）, 
which was prepared with a reversed-phase InertSustain C18, 3 µm, 100 × 2.1 mm column （GL Sci-
ence, Tokyo）.  The temperature of the autosampler and column oven was kept at 7℃ and 40℃, 
respectively.  The mobile phase for separation used a gradient method and consisted of a mobile 
phase A （20 mmol/l ammonium formate - water） and mobile phase B （20 mmol/l ammonium 
formate - methanol）.  A ow rate of 0.45 ml/min was used.  Mobile phase B started at 30％ 
and increased linearly to 100％ in 0-6 minutes.  Mobile phase B was maintained at 100％ 
for 6-8 minutes and then returned to 30％ and re-equilibrated in 8-10 minutes.  Electrospray 
ionization （ESI） was performed using an LC-MS/MS-8040 （Shimadzu, Kyoto, Japan） in positive 
Multiple Reaction Monitoring mode.  The probe voltage was set to ＋ 1.5 kV, the desolvation 
line temperature was set to 250℃, the block heater temperature was set to 400℃, and liquid 
nitrogen （purity ＞ 99.99％） was used in the nebulizer gas （3.0 l/min） and drying gas （15.0 l/
min）.  The mass transitions were m/z 445.2→ 109.0 for RAL, m/z 420.1→ 277.1 for DTG, m/
z 448.1→ 344.1 for EVG, 450.0→ 289.1 for BIC, and m/z 448.0→ 364.15 for RAL-d3.  Collision 
energies were : RAL, 19 V ; DTG, 27 V ; EVG, 34 V ; BIC, 23 V ; and IS, 19 V.  The analytical 
data were processed using LabSolutions LCMS software （Shimadzu, Kyoto, Japan）.
Method validation
　The selectivity, linearity, LLOQ, precision, carryover, dilution integrity, and stability of the analy-
sis methods were validated in accordance with the Guideline on Bioanalytical Method Validation 
in Pharmaceutical Development21）.  Calibration curves （CC） were generated using blank human 
plasma, a zero standard, and seven samples for the CC within the range of 0.5-1,250 ng/ml.  CC 
were created by plotting the peak area ratio （drug peak area/IS peak area） against each analyte 
concentration, using a linear regression model weighted with 1/x2.  The precision and accuracy of 
the analysis method were evaluated through the iterative analysis of the QC samples （LLQC, 
LQC, MQC, and HQC）.  The QC concentration was calculated from the CC.  Five replicates of 
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each QC sample were prepared, and the intra- and inter-day precision （coefcient of variation 
（CV） ％） and accuracy were calculated.  To ensure the concentration of the analyzed substance 
was within the quantication limit of the calibration curve, plasma samples were prepared by 
spiking with each analyte at 10,000 ng/ml.  The dilution control sample was diluted 10-fold with 
blank plasma, and ve repeat analyses were performed.  The sample handling stability was based 
on QC samples at two different concentrations （1 and 1,000 ng/ml）.  Short-term stability was 
measured using samples stored at 9℃ for 3 days, whereas long-term stability tests used samples 
stored at －30℃ for 30 days.  Freeze-thaw stability was measured in samples subjected to three 
freeze-thaw cycles prior to analysis.  Benchtop stability was measured at room temperature 
（22℃） for 4 h.  
Results
LC-MS/MS Chromatograms
　Interference peaks with the blank plasma were not observed in the retention times of the 
four INSTIs or IS.  The LLOQ and blank chromatogram were shown in Figure 1.  Using the 
chromatography conditions described above, the retention times for RAL, DTG, EVG, BIC, and 
IS were 3.52, 3.81, 5.36, 3.82, and 3.52 min, respectively.  
Fig. 1.   Typical multi-reaction monitoring chromatograms for raltegravir, dolutegravir, elvitegravir, 
bictegravir, and raltegravir-d3 （IS）: （A） standards at LLOQ （0.5 ng/ml each） for plasma ; （B） 
blank plasma sample.  IS, internal standard ; LLOQ, lower limit of quantification.
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Validation : Linearity, Precision, Accuracy, and Recovery
　The standard curves of the four INSTIs were analyzed with weighted （1/x2） least-square linear 
regression.  The correlation coefcient （r2） of the calibration curve for all drugs within the range 
of 0.5-1,250 ng/ml was ≥ 0.9904 （Table 1）.  In addition, the accuracy of the calibration curve was 
89.2％-111.7％, CV was 0.5％-7.3％, and the LLOQ was 0.5 ng/ml for all drugs.  The intra- and 
inter-day accuracy and CV of the four INSTI plasma samples were shown in Table 2.  The mean 
intra-day accuracy was 99.6％ ± 7.2％, and the precision （CV） was ≤ 18.5％.  The mean inter-day 
accuracy was 101.0％ ± 5.0％, and the precision （CV） was ≤ 10.3％.  The carryover measurement 
using blank human plasma （n＝ 5） after measurement of the maximum concentration sample 
（1,250 ng/ml） did not detect any of the four drugs.  The mean accuracy of the 10-fold diluted 













Raltegravir 0.5 0.50 ± 0.004  99.7 0.7 0.9969
5 5.2 ± 0.3 104.2 5.1
20 21 ± 0.5 102.8 2.6
50 52 ± 0.9 103.5 1.8
250 226 ± 1  90.4 0.5
500 501 ± 8 100.1 1.6
1,250 1,281 ± 23 102.5 1.8
Dolutegravir 0.5 0.49 ± 0.002  98.9 0.5 0.9937
5 5.3 ± 0.4 106.6 7.0
20 21 ± 0.2 105.2 1.0
50 54 ± 0.4 107.4 0.8
250 254 ± 8 101.4 3.3
500 469 ± 19  94.0 4.0
1,250 1,128 ± 64  90.2 5.7
Elvitegravir 0.5 0.50 ± 0.01  99.4 1.2 0.9904
5 5.2 ± 0.4 103.9 7.3
20 22 ± 0.3 111.7 1.4
50 56 ± 0.7 111.7 1.3
250 233 ± 9  93.0 4.0
500 468 ± 20  93.6 4.2
1,250 1,140 ± 54  91.2 4.8
Bictegravir 0.5 0.05 ± 0.01  99.3 1.4 0.9912
5 5.4 ± 0.4 107.7 7.3
20 22 ± 0.4 110.7 1.8
50 54 ± 0.7 108.9 1.3
250 223 ± 6  89.2 2.7
500 482 ± 18  96.3 3.7
1,250 1,169 ± 37  93.6 3.2
SD ; standard deviation, CV ; coefficient of variation.
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plasma samples （n＝ 5） for each drug were 102.6％-107.5％, and the CV were 1.1％-2.3％.  The 
stability data for the plasma samples under various conditions were shown in Table 3.  The mean 
accuracy was within 85％-115％, and the precision （CV） was＜ 15％ in all of the stability samples 
tested after three freeze-thaw cycles, 4 h at room temperature （22℃）, 30 days at -30℃, and 72 
h at 9℃.  The mean recovery rate of RAL, DTG, EVG, and BIC in HQC was 105.5％, 86.2％, 
74.7％, and 72.2％, respectively.  The matrix effect （ME） CV for each drug was 2.6％ （RAL）, 
1.9％ （DTG）, 6.5％ （EVG）, and 1.0％ （BIC）, and was less than 15％ for all drugs （Table 4）.
Application of the Method in Clinical Samples
　The developed analysis method was used to determine the INSTI concentrations in clinical 
samples.  The patient proles and respective drugs were shown in Table 5.  The clinical samples 
were collected from six patients treated with ART, including RAL, DTG, EVG, and BIC.  All 
clinical samples were analyzed without any issues.
Discussion
　In this study, a method was developed for the simultaneous quantification of four INSTIs, 
which are recommended in HIV treatment guidelines.  The resolution of the four INSTIs 
achieved by high-performance liquid chromatography （HPLC） was well maintained by the Inert-
Sustain C18 column.  Reversed-phase chromatography columns （C18 columns） have been widely 





Intra-assay （1 day, n＝ 5） Inter-assay （3 days, n＝ 5）
Observed 
concentration 














Raltegravir LLQC 0.5 0.59 ± 0.11 117.4 18.5 0.54 ± 0.03 107.5 6.5
LQC 1.0 1.1 ± 0.1 108.2 9.4 1.0 ± 0.1 102.1 10.0
MQC 100 98 ± 2 98.0 2.3 109 ± 2 108.8 1.5
HQC 1,000 1,014 ± 9 101.5 1.0 1,027 ± 21 102.8 2.0
Dolutegravir LLQC 0.5 0.47 ± 0.05 94.8 10.1 0.55 ± 0.03 109.7 4.6
LQC 1.0 1.1 ± 0.1 105.0 10.5 1.0 ± 0.1 102.2 10.3
MQC 100 97 ± 2 96.7 1.8 95 ± 3 95.4 3.7
HQC 1,000 943 ± 13 94.3 1.4 982 ± 19 98.2 2.0
Elvitegravir LLQC 0.5 0.47 ± 0.06 93.6 12.0 0.51 ± 0.05 103.0 8.8
LQC 1.0 1.0 ± 0.1 93.7 10.3 1.0 ± 0.1 98.4 9.8
MQC 100 97 ± 3 97.3 3.0 96 ± 2 96.0 1.7
HQC 1,000 926 ± 24 92.6 2.6 924 ± 18 92.4 1.9
Bictegravir LLQC 0.5 0.56 ± 0.04 112.3 7.9 0.53 ± 0.03 105.1 6.3
LQC 1.0 1.0 ± 0.1 96.2 5.7 1.0 ± 0.1 94.9 5.5
MQC 100 99 ± 2 99.3 2.2 103 ± 2 102.6 1.7
HQC 1,000 926 ± 18 92.6 1.9 977 ± 10 97.7 1.0
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used in previous reports of anti-HIV drug chromatographic separation12-20）.  The quantication 
limit of the simultaneous measurement of multiple anti-HIV drugs, including INSTIs in human 
plasma using LC-MS/MS, has been reported to be 5 ng/ml or more.  Tsuchiya, et al. measured 
RAL, EVG, and DTG in human plasma and CSF, and the measurement range was 5-1,500 ng/
Table 3.  Stability studies of quality control samples
Stability Analyte QC Level









Raltegravir LQC 0.9 ± 0.1 87.7 10.6
HQC 1,086 ± 7 108.6 0.9
Dolutegravir LQC 1.0 ± 0.03 94.5 2.8
HQC 914 ± 14 91.4 1.5
Elvitegravir LQC 1.0 ± 0.04 97.6 4.2
HQC 987 ± 10 98.7 1.1
Bictegravir LQC 1.0 ± 0.04 101.6 4.0




Raltegravir LQC 1.0 ± 0.1 102.1 8.8
HQC 971 ± 16 97.1 1.7
Dolutegravir LQC 1.0 ± 0.1 96.8 5.3
HQC 872 ± 22 87.2 2.5
Elvitegravir LQC 1.0 ± 0.1 95.6 5.1
HQC 874 ± 9 87.4 1.0
Bictegravir LQC 1.0 ± 0.1 96.2 12.7
HQC 1,055 ± 15 105.5 1.4
Long-term
（30 days at －30℃）
n＝ 5
Raltegravir LQC 1.0 ± 0.1 96.3 12.3
HQC 916 ± 7 91.6 0.8
Dolutegravir LQC 0.9 ± 0.1 85.7 14.9
HQC 1,026 ± 38 102.6 3.7
Elvitegravir LQC 1.0 ± 0.1 94.6 14.1
HQC 992 ± 30 99.2 3.1
Bictegravir LQC 0.9 ± 0.1 89.5 8.8
HQC 961 ± 4 96.1 0.5
Processed sample
（72 h at 9℃）
n＝ 5
Raltegravir LQC 1.1 ± 0.1 108.2 9.4
HQC 1,081 ± 12 108.1 1.1
Dolutegravir LQC 1.1 ± 0.1 105.0 10.5
HQC 910 ± 12 91.0 1.3
Elvitegravir LQC 0.9 ± 0.1 93.7 10.3
HQC 984 ± 12 98.4 1.2
Bictegravir LQC 1.0 ± 0.1 96.3 5.7
HQC 871 ± 9 87.1 1.1
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ml in plasma and 1-200 ng/ml in CSF18）.  Penchala, et al. measured cobicistat （COBI）, DTG, and 
EVG in HIV-negative volunteers with a range of 10-4,000 ng/ml19）.  Simiele, et al. measured 18 
anti-HIV agents, including RAL, EVG, and DTG, and reported concentrations ranging from 7.8-
703 ng/ml20）.  INSTIs inhibit enzyme activity by chelating two metal ions present at the center of 
integrase22）.  Therefore, it is possible to detect INSTIs with high sensitivity by using a metal-free 
column to remove the inuence of the inner wall of the column hardware and adsorption to 
the lter metal.  The simultaneous measurement of INSTIs described above use a reversed-phase 
chromatography column （C18）, but it is not a metal-free column.  The selection of a metal-free 
column is one of the reasons for the high sensitivity of the method used in this study.  Another 
factor was the use of methanol instead of acetonitrile in the deproteinization process.  For the 
deproteinization in the INSTI assay described above, Penchala et al. used tert–butyl methyl ether 
（TBME）19）, whereas the other studies used acetonitrile.  Acetonitrile is generally more efcient 
at deproteinization than methanol.  Since the solubility of the four INSTIs was higher in metha-
nol than in acetonitrile, the choice of methanol for deproteinization was considered to be one of 
the reasons that contributed to the high sensitivity.  The preparation of samples for measuring 
the plasma concentration of the drug with LC-MS/MS requires a lot of time and effort.  In 
this study, deproteinization was performed using a fully automated sample preparation apparatus, 
which reduces the risk of measurement variations and operation errors due to the operator’s 












Raltegravir HQC 1,000 105.5 ± 43.1 105.0 ± 2.7 2.6
Dolutegravir HQC 1,000  86.2 ± 19.5 136.7 ± 2.6 1.9
Elvitegravir HQC 1,000 74.7 ± 7.0 149.0 ± 9.6 6.5
Bictegravir HQC 1,000  72.2 ± 14.6 121.8 ± 1.3 1.0















1 DTG/TAF/FTC Dolutegravir  50, QD 20 8,710 23 574
2 EVG/COBI/TAF/FTC Elvitegravir 150, QD 18 1,688 106 479
3 DTG/ABC/3TC Dolutegravir  50, QD 23 3,365 700 954
4 RAL/ABC/3TC Raltegravir 400, BID 12   847 42 826
5 BIC/TAF/FTC Bictegravir  50, QD 24 8,139 182 554
6 BIC/TAF/FTC Bictegravir  50, QD 19 7,353 71 593
3TC ; lamivudine, ABC ; abacavir, ART ; antiretroviral therapy, BIC ; bictegravir, BID ; bis in die （twice daily）, 
COBI ; cobicistat, DTG ; dolutegravir, EVG ; elvitegravir, FTC ; emtricitabine, QD ; quaque die （once daily）, 
TAF ; tenofovir alafenamide
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procedure.  Measurement of illegal drugs and metabolites using CLAM, a fully automated 
sample preparation method23）, has been reported, but it has not yet been applied to anti-HIV 
drugs.  The fully automatic pretreatment equipment is useful from the viewpoint of avoiding the 
risk of exposure to HIV infections of the measurer.  The measurement range of the four INSTIs 
in the developed method was 0.5-1,250 ng/ml, and the selection of an appropriate column and 
pretreatment likely contributed to its high sensitivity.  
　The developed analysis method was used to determine the INSTI concentrations in six clinical 
patients treated with ART, including RAL, DTG, EVG, and BIC.  By measuring the patient’s 
plasma drug concentration, it was possible to conrm the therapeutic effect and adherence and 
avoid potential side effects.  Patient No. 1 had mild insomnia.  The steady-state trough level 
of DTG at 50 mg once daily in adult HIV-infected patients is about 1.11 µg/ml5）.  It has been 
reported that high plasma concentrations of DTG are associated with adverse reactions in the 
central nervous system （CNS）24）.  The plasma concentration of DTG in this patient was high 
（8,710 ng/ml） and led to the assumption that the insomnia was an adverse reaction of DTG. 
Patient No. 2 received EVG/COBI/TAF/FTC on an empty stomach, and the level of HIV RNA 
was determined to be 106 copies/ml.  Taking EVG on an empty stomach reduces the AUC by 
26％-46％7）.  The plasma concentration of the drug was measured, and a drug resistance test 
was performed to conrm the absorption of EVG.  The package insert states that the trough 
level of EVG is 0.29 µg/ml7）.  The plasma concentration of EVG was maintained at 1,688 ng/ml, 
and no drug-resistant mutations were detected.  The HIV RNA blips were repeatedly detected 
in Patients No. 3 and 4, and therefore, the plasma concentrations were measured to check the 
adherence and therapeutic effect （the package insert states that the trough level of RAL is 
63 ng/ml）3）.  After completing tuberculosis treatment with rifampicin, Patient No. 5 switched from 
DTG （twice daily）/TDF/FTC to BIC/TAF/FTC.  The plasma concentration of BIC was mea-
sured to determine the effect of the drug interactions caused by rifampicin.  Treatment of Patient 
No. 6 with EVG/c/TAF/FTC failed to reduce the levels of HIV RNA from 70 to 400 copies/ml. 
Therefore, the regimen for Patient No. 6 was changed to BIC/TAF/FTC, and the drug plasma 
concentration was measured to determine the therapeutic effect.  Although the plasma concentra-
tions of the drug for Patients No. 5 and 6 were higher than the value of the trough concentra-
tion （2,610 ng/ml） stated in the package insert9）, there were no adverse reactions.
　Assays to simultaneously measure the four INSTIs, including BIC, have not yet been reported. 
INSTIs are the recommended anti-HIV agent in current HIV treatment guidelines, and therefore, 
the simultaneous measurement of four INSTIs in a single assay system is applicable to many 
patients.  Especially because the new INSTI BIC is being prescribed more often in Japan. 
Therefore, the simultaneous determination of anti-HIV drugs, including BIC, will be important 
for many patients in the future.
　We developed a method to simultaneously quantify RAL, DTG, EVG, and BIC, which used 
simple sample processing and a highly sensitive LC-MS/MS analysis.  This method is suitable 
for conrming the efcacy and safety of drugs in clinical practice by monitoring their plasma 
concentrations in HIV-infected patients.
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